Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06314958 · ClinicalTrials.gov registry record
Stage II/III Colorectal Cancer Recurrence
A clinical trial of Colorectal Cancer and Colorectal Adenocarcinoma, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 400
- Enrollment target
- 4
- Study locations
NCT06314958: Recruiting study of Colorectal Cancer and Colorectal Adenocarcinoma, sponsored by City of Hope Medical Center.
NCT06314958 is a study of Colorectal Cancer and Colorectal Adenocarcinoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 400 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (74% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06314958, a study of Colorectal Cancer and Colorectal Adenocarcinoma, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
Primary Outcome
Time from treatment completion to development of recurrence (or death)
Conditions Studied
Interventions
- OTHER CENSURE
Study Locations (4)
Other
- Second Affiliated Hospital of Dalian Medical University - Dalian
- Barcelona University - Barcelona
- La Paz University Hospital - Madrid
California
- City of Hope Medical Center - Monrovia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2026-06-18 |
What NCT06314958 shows while recruiting
NCT06314958 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (74% lower).
The record links to 5 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which CENSURE is the first listed.
NCT06314958 reports a single indexed study location in Other, California.
Frequently Asked Questions
What is clinical trial NCT06314958 about?
NCT06314958 is a clinical study titled "Stage II/III Colorectal Cancer Recurrence". This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
What is the current status of trial NCT06314958?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2023-03-15. Estimated completion is 2026-06-18.
What conditions does trial NCT06314958 study?
This clinical trial studies the following conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Recurrent.
What interventions are being tested in trial NCT06314958?
The interventions under investigation include: CENSURE (OTHER).
Who is sponsoring clinical trial NCT06314958?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06314958 being conducted?
This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06314958's enrollment target sits among peer trials
400 93rd of 381 higher than 284 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI